Fluoxetine and Sertraline Potently Neutralize the Replication of Distinct SARS-CoV-2 Variants - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Viruses Year : 2024

Fluoxetine and Sertraline Potently Neutralize the Replication of Distinct SARS-CoV-2 Variants

Abstract

The pandemic caused by SARS-CoV-2 is still a major health problem. Newly emerging variants and long-COVID-19 represent a challenge for the global health system. In particular, individuals in developing countries with insufficient health care need easily accessible, affordable and effective treatments of COVID-19. Previous studies have demonstrated the efficacy of functional inhibitors of acid sphingomyelinase against infections with various viruses, including early variants of SARS-CoV-2. This work investigated whether the acid sphingomyelinase inhibitors fluoxetine and sertraline, usually used as antidepressant molecules in clinical practice, can inhibit the replication of the former and recently emerged SARS-CoV-2 variants in vitro. Fluoxetine and sertraline potently inhibited the infection with pseudotyped virus-like particles and SARS-CoV-2 variants D614G, alpha, delta, omicron BA.1 and omicron BA.5. These results highlight fluoxetine and sertraline as priority candidates for large-scale phase 3 clinical trials at different stages of SARS-CoV-2 infections, either alone or in combination with other medications.
Fichier principal
Vignette du fichier
Thümmler et al 2024.pdf (1.29 Mo) Télécharger le fichier
Origin Publisher files allowed on an open archive
Licence

Dates and versions

inserm-04604504 , version 1 (07-06-2024)

Licence

Identifiers

Cite

Laura Thümmler, Nadine Beckmann, Carolin Sehl, Matthias Soddemann, Peer Braß, et al.. Fluoxetine and Sertraline Potently Neutralize the Replication of Distinct SARS-CoV-2 Variants. Viruses, 2024, 16 (4), pp.545. ⟨10.3390/v16040545⟩. ⟨inserm-04604504⟩
7 View
3 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More